BioRestorative Therapies, Inc. – NASDAQ:BRTX
BioRestorative Therapies stock price today
BioRestorative Therapies stock price monthly change
BioRestorative Therapies stock price quarterly change
BioRestorative Therapies stock price yearly change
BioRestorative Therapies key metrics
Market Cap | 10.72M |
Enterprise value | 11.86M |
P/E | -0.72 |
EV/Sales | 57.35 |
EV/EBITDA | -0.42 |
Price/Sales | 63.99 |
Price/Book | 0.83 |
PEG ratio | N/A |
EPS | -0.86 |
Revenue | 149.5K |
EBITDA | -13.42M |
Income | -4.11M |
Revenue Q/Q | 11.82% |
Revenue Y/Y | 10.65% |
Profit margin | -13526.42% |
Oper. margin | -13850.38% |
Gross margin | 34.36% |
EBIT margin | -13850.38% |
EBITDA margin | -8979.25% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioRestorative Therapies stock price history
BioRestorative Therapies stock forecast
BioRestorative Therapies financial statements
| Jun 2023 | 64.5K | -2.98M | -4621.01% |
|---|---|---|---|
| Sep 2023 | 30.7K | -83.33K | -271.44% |
| Dec 2023 | 19.3K | 1.17M | 6075.45% |
| Mar 2024 | 35K | -2.22M | -6352.16% |
| Sep 2025 | 585K | 0 | |
|---|---|---|---|
| Oct 2025 | 585K | 0 | |
| Dec 2025 | 608K | 0 | |
| Mar 2026 | 646.87K | 0 |
Analysts Price target
Financials & Ratios estimates
| 2022-08-15 | -1.28 | -1.28 |
|---|---|---|
| 2022-11-14 | -1.45 | -1.28 |
| 2023-03-27 | -0.99032 | -1.19 |
| Jun 2023 | 13300297 | 896.43K | 6.74% |
|---|---|---|---|
| Sep 2023 | 13801101 | 975.03K | 7.06% |
| Dec 2023 | 12611720 | 2.60M | 20.67% |
| Mar 2024 | 17951466 | 3.44M | 19.21% |
| Jun 2023 | -1.13M | 665.80K | 411.70K |
|---|---|---|---|
| Sep 2023 | -1.17M | -23.05K | 1.85M |
| Dec 2023 | -1.77M | 100.66K | 83.07K |
| Mar 2024 | -2.31M | -4.92M | 7.51M |
BioRestorative Therapies alternative data
| Aug 2023 | 10 |
|---|---|
| Sep 2023 | 10 |
| Oct 2023 | 10 |
| Nov 2023 | 10 |
| Dec 2023 | 10 |
| Jan 2024 | 10 |
| Feb 2024 | 10 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 11 |
BioRestorative Therapies other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 5200 | 0 |
| Aug 2023 | 4954 | 0 |
| Sep 2023 | 25887 | 0 |
| Nov 2023 | 0 | 278 |
| Dec 2023 | 0 | 250 |
| Feb 2024 | 280000 | 0 |
| Apr 2024 | 8308 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SILVA FRANCISCO director, officer.. | Common Stock | 6,600 | $1.25 | $8,250 | ||
Purchase | SILVA FRANCISCO director, officer.. | Common Stock | 1,232 | $1.17 | $1,441 | ||
Purchase | SILVA FRANCISCO director, officer.. | Common Stock | 476 | $1.13 | $538 | ||
Purchase | BROADRICK DALE 10 percent owner | Common Stock | 86,041 | $1.32 | $113,574 | ||
Purchase | BROADRICK DALE 10 percent owner | Common Stock | 83,626 | $1.34 | $112,059 | ||
Purchase | BROADRICK DALE 10 percent owner | Common Stock | 73,959 | $1.25 | $92,449 | ||
Purchase | BROADRICK DALE 10 percent owner | Common Stock | 36,374 | $1.38 | $50,196 | ||
Sale | BROADRICK DALE 10 percent owner | Common Stock | 250 | $1.88 | $469 | ||
Sale | BROADRICK DALE 10 percent owner | Common Stock | 278 | $1.89 | $525 | ||
Purchase | BROADRICK DALE 10 percent owner | Common Stock | 10,000 | $1.66 | $16,600 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
-
What's the price of BioRestorative Therapies stock today?
One share of BioRestorative Therapies stock can currently be purchased for approximately $1.53.
-
When is BioRestorative Therapies's next earnings date?
Unfortunately, BioRestorative Therapies's (BRTX) next earnings date is currently unknown.
-
Does BioRestorative Therapies pay dividends?
No, BioRestorative Therapies does not pay dividends.
-
How much money does BioRestorative Therapies make?
BioRestorative Therapies has a market capitalization of 10.72M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.7% to 145.8K US dollars. BioRestorative Therapies made a loss 10.42M US dollars in net income (profit) last year or -$1.19 on an earnings per share basis.
-
What is BioRestorative Therapies's stock symbol?
BioRestorative Therapies, Inc. is traded on the NASDAQ under the ticker symbol "BRTX".
-
What is BioRestorative Therapies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioRestorative Therapies?
Shares of BioRestorative Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioRestorative Therapies's key executives?
BioRestorative Therapies's management team includes the following people:
- Mr. Francisco J. Silva Vice President of R&D, Sec. and Director(age: 50, pay: $207,550)
- Mr. Lance Alstodt Chairman, Pres & Chief Executive Officer(age: 54, pay: $64,320)
-
How many employees does BioRestorative Therapies have?
As Jul 2024, BioRestorative Therapies employs 11 workers, which is 10% more then previous quarter.
-
When BioRestorative Therapies went public?
BioRestorative Therapies, Inc. is publicly traded company for more then 12 years since IPO on 5 Dec 2012.
-
What is BioRestorative Therapies's official website?
The official website for BioRestorative Therapies is biorestorative.com.
-
Where are BioRestorative Therapies's headquarters?
BioRestorative Therapies is headquartered at 40 Marcus Drive, Melville, NY.
-
How can i contact BioRestorative Therapies?
BioRestorative Therapies's mailing address is 40 Marcus Drive, Melville, NY and company can be reached via phone at +63 17608100.
BioRestorative Therapies company profile:
BioRestorative Therapies, Inc.
biorestorative.comNASDAQ
11
Biotechnology
Healthcare
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Melville, NY 11747
CIK: 0001505497
ISIN: US0906556065
CUSIP: 090655606
